AB Science Overview
- Year Founded
-
2001
- Status
-
Public
- Employees
-
40
- Stock Symbol
-
AB
- Share Price
-
$0.69
- (As of Friday Closing)
AB Science General Information
Description
AB Science is a clinical-stage pharmaceutical company that has developed a diversified portfolio of medicines targeting unmet medical needs, based on two platforms. Masitinib platform: It is based on masitinib, a selective protein kinase inhibitor in development for neurodegenerative diseases, oncology, & inflammatory diseases. It has the clinical development of masitinib in neurodegenerative diseases (specifically Alzheimer's disease, amyotrophic lateral sclerosis, & progressive forms of multiple sclerosis). ALDH/Microtubule Platform: It is a portfolio of synthetic agents that target cancer cells by destabilising microtubules, which are essential for cell division & cancer stem cells, by inhibiting enzymes that are essential for maintaining their physiological state & survival.
Contact Information
Website
www.ab-science.comCorporate Office
- 3, Avenue George V
- 75008 Paris
- France
Corporate Office
- 3, Avenue George V
- 75008 Paris
- France
AB Science Timeline
AB Science Stock Performance
As of 13-Nov-2026, AB Science’s stock price is $0.69. Its current market cap is $66.7M with 96.5M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.69 | $0.76 | $0.55 - $1.89 | $66.7M | 96.5M | 253K | -$0.08 |
AB Science Financials Summary
As of 30-Jun-2026, AB Science has a trailing 12-month revenue of $1.35M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 80,617 | 135,874 | 69,514 | 200,487 |
| Revenue | 1,350 | 1,324 | 1,160 | 1,050 |
| EBITDA | (6,458) | 1,887 | (5,321) | (10,644) |
| Net Income | (6,310) | (1,756) | (8,474) | (12,969) |
| Total Assets | 20,658 | 28,808 | 24,115 | 28,187 |
| Total Debt | 22,303 | 22,257 | 19,205 | 20,937 |
AB Science Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
AB Science Comparisons
Industry
Financing
Details
AB Science Competitors (93)
One of AB Science’s 93 competitors is Harmony Biosciences Holdings, a Formerly VC-backed company based in Plymouth Meeting, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Harmony Biosciences Holdings | Formerly VC-backed | Plymouth Meeting, PA | ||||
| Blueprint Medicines | Formerly VC-backed | Cambridge, MA | ||||
| Compass Therapeutics | Formerly VC-backed | Boston, MA | ||||
| Gilead | Formerly VC-backed | Foster City, CA | ||||
| Xenetic Biosciences | Corporation | Framingham, MA |
AB Science Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
AB Science Patents
AB Science Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025027051-A1 | Sphingosine-1-phosphate lyase inhibitors for use in the treament of neurodegenerative diseases | Inactive | 31-Jul-2023 | ||
| AU-2024225818-A1 | Compounds for treating myeloid diseases with chromosomal abnormalities | Pending | 24-Feb-2023 | ||
| EP-4669317-A1 | Compounds for treating myeloid diseases with chromosomal abnormalities | Pending | 24-Feb-2023 | ||
| WO-2024175803-A1 | Compounds for treating myeloid diseases with chromosomal abnormalities | Inactive | 24-Feb-2023 | ||
| AU-2024205985-A1 | Tubulin polymerization inhibitors | Pending | 04-Jan-2023 | A61P35/00 |
AB Science Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
AB Science ESG
Risk Overview
Risk Rating
Updated February, 29, 2024
32.49 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 16,421
Rank
Percentile
Pharmaceuticals
Industry
of 928
Rank
Percentile
Pharmaceuticals
Subindustry
of 456
Rank
Percentile
AB Science FAQs
-
When was AB Science founded?
AB Science was founded in 2001.
-
Where is AB Science headquartered?
AB Science is headquartered in Paris, France.
-
What is the size of AB Science?
AB Science has 40 total employees.
-
What industry is AB Science in?
AB Science’s primary industry is Drug Discovery.
-
Is AB Science a private or public company?
AB Science is a Public company.
-
What is AB Science’s stock symbol?
The ticker symbol for AB Science is AB.
-
What is the current stock price of AB Science?
As of 13-Nov-2026 the stock price of AB Science is $0.69.
-
What is the current market cap of AB Science?
The current market capitalization of AB Science is $66.7M.
-
What is AB Science’s current revenue?
The trailing twelve month revenue for AB Science is $1.35M.
-
Who are AB Science’s competitors?
Harmony Biosciences Holdings, Blueprint Medicines, Compass Therapeutics, Gilead, and Xenetic Biosciences are some of the 93 competitors of AB Science.
-
What is AB Science’s annual earnings per share (EPS)?
AB Science’s EPS for 12 months was -$0.08.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
